Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um ensaio randomizado, adaptativo, com variação de dose e aberto de novos regimes para o tratamento da tuberculose pulmonar (RAD-TB)

Um ensaio de fase 2 randomizado, adaptativo, com variação de dose e aberto de novos regimes para o tratamento da tuberculose pulmonar

A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB).

A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care [(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)].

The study will run for 52 weeks, inclusive of 26 weeks of TB treatment comprised of 8 weeks of study treatment (experimental or SOC, based on treatment arm assignment) followed by 18 weeks of SOC continuation phase treatment with 346 participants in Wave 1: 49-50 participants in each experimental treatment arm and 98-100 participants in the SOC treatment arm.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

341

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Gaborone, Botsuana, 0000
        • 12701, Gaborone CRS
      • Porto Alegre, Brasil, 91350
        • 12201, Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
      • Rio de Janeiro, Brasil, 21040
        • 12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
      • Cavite, Filipinas, 4118
        • 31981, TB HIV Innovations and Clinical Research Foundation Corp.
      • Port-au-Prince, Haiti, 6110
        • 30022, Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
      • Port-au-Prince, Haiti, 6110
        • 31730, GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
      • Blantyre, Malauí
        • 30301, Blantyre CRS
      • Lilongwe, Malauí, A-104
        • 12001, Malawi CRS
      • Mexico City, México, 14080
        • 32078, Nutrición-Mexico CRS
      • Lima, Peru, 15063
        • 11301, Barranco CRS
      • Lima, Peru
        • 11302, San Miguel CRS San Miguel
    • Lima Province
      • Lima, Lima Province, Peru, 15234
        • 31985, Socios En Salud Sucursal Perú CRS
      • Eldoret, Quênia, 30100
        • 12601, Moi University Clinical Research Center (MUCRC) CRS
      • Kericho, Quênia, 20200
        • 12501, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS
      • Bangkok, Tailândia, 10700
        • 5115, Siriraj Hospital, Mahidol University NICHD CRS
      • Chiang Mai, Tailândia, 50200
        • 31784, Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
      • Pathum Wan, Tailândia, 10330
        • 31802, Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
    • Changwat Chiang Rai
      • Chiang Rai, Changwat Chiang Rai, Tailândia, 57000
        • 5116 Chiangrai Prachanukroh Hospital NICHD CRS
      • Kampala, Uganda
        • 12401, Joint Clinical Research Centre (JCRC)/Kampala CRS
      • Kampala, Uganda
        • 30293 MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
      • Hanoi, Vietnã, 100000
        • 32483 National Lung Hospital CRS
      • Harare, Zimbábue
        • 30313, Milton Park CRS
      • Cape Town, África do Sul, 6850
        • 31793, South African Tuberculosis Vaccine Initiative (SATVI) CRS
      • Cape Town, África do Sul, 7700
        • 31792, University of Cape Town Lung Institute (UCTLI) CRS
      • Durban, África do Sul, 4001
        • 31422, CAPRISA eThekwini CRS
      • Durban, África do Sul, 4052
        • 11201, Durban International CRS
      • Johannesburg, África do Sul, 1862
        • 12301, Soweto ACTG CRS
      • Johannesburg, África do Sul, 2193
        • 11101, Wits Helen Joseph (WITS HJH) CRS
      • Rustenburg, África do Sul
        • 31684, Rustenburg CRS
      • Pune, Índia, 411001
        • 31441, Byramjee Jeejeebhoy Government Medical College (BJGMC) CRS

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Pulmonary TB (among individuals either without history of prior TB treatment or with history of TB treatment completed more than 2 years prior to study entry), identified within 7 days prior to study entry by at least one sputum specimen positive for Mtb by Xpert. Semiquantitative Mtb results of "medium" or "high" from Xpert MTB/RIF Ultra are required.

  2. Pulmonary TB with documented INH susceptibility (by Line Probe Assay (LPA) or Xpert MTB/XDR or other validated molecular test) and with documented RIF susceptibility (by LPA or Xpert MTB/RIF or Xpert MTB/RIF Ultra or other validated molecular test) within 7 days prior to study entry.

  3. Documentation of HIV-1 infection status, as below:

    Presence or absence of HIV-1 infection, as documented by:

    • Any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, any time prior to study entry. AND for a positive result confirmation by one of the following:
    • A second antibody test from different manufacturers or based on different principles and epitopes (combination antigen-antibody-based rapid tests may be used), or
    • HIV-1 antigen, or
    • Plasma HIV-1 RNA viral load, or
    • A licensed Western blot
  4. For individuals with HIV: CD4+ cell count ≥100 cells/mm3 based on testing performed within 30 days prior to study entry.

  5. For individuals with HIV: Currently being treated with dolutegravir-based antiretroviral therapy (ART), or plan to initiate dolutegravir-based ART at or before study week 8.

  6. Individuals age ≥18 years.

  7. The following laboratory values obtained within 7 days prior to study entry at any network-approved non-U.S. laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs:

    • Serum or plasma alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN)
    • Serum or plasma total bilirubin ≤2 times ULN
    • Serum or plasma creatinine ≤2 times ULN
    • Serum or plasma potassium ≥3.5 mEq/L
    • Serum or plasma magnesium ≥1.0 mEq/L (≥0.500 mmol/L)
    • Absolute neutrophil count (ANC) ≥1500/mm^3
    • Hemoglobin ≥9.0 g/dL
    • Platelet count ≥100,000/mm^3
    • Negative for, hepatitis B surface antigen (HBsAg)
    • Negative for hepatitis C virus (HCV) antibody (or if HCV antibody positive, must have a negative HCV PCR)
  8. For female study candidates who are of reproductive potential, negative pregnancy test (urine HCG or serum β-HCG) within 3 days (72 hours) prior to entry by any network-approved non-U.S. laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs.

    Females who are of reproductive potential and who participate in sexual activity that could lead to pregnancy must agree to use at least two of the following forms of birth control while receiving TB study medications and for 12 months after stopping study medications:

    • Male or female condoms
    • Diaphragm or cervical cap (with spermicide, if available)
    • Intrauterine device (IUD) or intrauterine system (IUS)
    • Hormone-based birth control (e.g., oral contraceptives, Depo-Provera, NuvaRing, implants)

    Female study candidates who are of reproductive potential, but who abstain from sexual activity that could lead to pregnancy require no additional contraception.

    Female study candidates who are not of reproductive potential are eligible without requiring the use of contraceptives. Self-reported history is acceptable documentation of menopause (i.e., at least 1 year amenorrheic), hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; these candidates are all considered not of reproductive potential.

  9. For male study candidates who engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-pregnant sexual partners of reproductive potential to use effective contraceptives while the individual is on study and for 90 days after experimental treatment discontinuation.

    For male study candidates who have undergone successful vasectomy with documented azoospermia or have documented azoospermia for any other reason, are eligible without requiring the use of contraceptives.

  10. For male study candidates with pregnant partners, willingness to use condoms during vaginal intercourse while on study and for 90 days after experimental treatment discontinuation.

  11. For male study candidates, willingness to refrain from sperm donation while on study and for 90 days after experimental treatment discontinuation.

  12. Documentation of Karnofsky performance score ≥60 obtained within 14 days prior to study entry.

  13. Chest x-ray obtained within 14 days prior to study entry.

  14. A verifiable address or residence readily accessible for visiting, and willingness to inform the study team of any change of address during study treatment and follow-up period.

  15. Ability and willingness of individual to provide informed consent.

Exclusion Criteria:

  1. More than cumulative 7 days of treatment directed against active TB for the current TB episode in the 60 days preceding study entry.
  2. Current extrapulmonary TB, in the opinion of the investigator.
  3. QTcF interval >450 ms within 7 days prior to study entry.
  4. History of or ongoing heart failure.
  5. Personal or family history of congenital QT prolongation.
  6. History of known, untreated, ongoing hypothyroidism.
  7. History of or ongoing bradyarrhythmia.
  8. History of torsades de pointes.
  9. Current Grade 2 or higher peripheral neuropathy.
  10. Other medical conditions (e.g., diabetes, liver or kidney disease, blood disorders, chronic diarrhea), in the opinion of the site investigator, in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.
  11. Pregnant or breastfeeding or planning to become pregnant within the next 12 months.
  12. Weight <35 kg.
  13. Unable to take oral medications.
  14. Taking any of prohibited medications.
  15. Known allergy/sensitivity or any hypersensitivity to components of investigational agents or their formulation.
  16. Active drug or alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  17. Taking an investigational drug or vaccine within 30 or more days prior to study entry.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Arm 1: Standard of Care (SOC)
  • Weeks 1-8: INH 300 mg, RIF 600 mg, PZA weight-based, EMB weight-based
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

Outros nomes:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Outros nomes:
  • RIF

PZA will be administered as 500 mg tablets, based on weight, orally once daily.

Outros nomes:
  • PZA

EMB will be administered as 400 mg tablets, based on weight, orally once daily.

Outros nomes:
  • EMB
Experimental: Arm 2: Bedaquiline (BDQ), Pretomanid (Pa), and Linezolid (LZD)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, LZD 600 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

Outros nomes:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Outros nomes:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Outros nomes:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Outros nomes:
  • Pa

LZD 600 mg will be administered as one 600 mg tablet orally once daily.

Outros nomes:
  • LZD
Experimental: Arm 3A: BDQ, Pa and TBI-223 (1200 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 1200 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

Outros nomes:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Outros nomes:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Outros nomes:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Outros nomes:
  • Pa

TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.

TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.

Experimental: Arm 3B: BDQ, Pa and TBI-223 (2400 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 2400 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

Outros nomes:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Outros nomes:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Outros nomes:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Outros nomes:
  • Pa

TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.

TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.

Experimental: Arm 4A: BDQ, Pa and Sutezolid (SZD) (800 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 800 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

Outros nomes:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Outros nomes:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Outros nomes:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Outros nomes:
  • Pa

SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.

Outros nomes:
  • SZD

SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.

Outros nomes:
  • SZD
Experimental: Arm 4B: BDQ, Pa and SZD (1600 mg)
  • Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 1600 mg
  • Weeks 9-26: INH 300 mg, RIF 600 mg (or weight-based dosing following WHO guidance)

INH 300 mg will be administered as one tablet orally once daily.

Outros nomes:
  • INH

RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Outros nomes:
  • RIF

BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Outros nomes:
  • BDQ

Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Outros nomes:
  • Pa

SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.

Outros nomes:
  • SZD

SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.

Outros nomes:
  • SZD

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Difference in mean log10 (Time to positivity (TTP)) slope from longitudinal mycobacteria growth indicator tube (MGIT) liquid culture measurements over the first 6 weeks of treatment
Prazo: Weeks 0, 1, 2, 3, 4 and 6

for each experimental treatment arm compared to the SOC treatment arm.

Weeks 0, 1, 2, 3, 4 and 6
Difference in the cumulative proportion of participants having at least one new Grade 3 or higher adverse event (AE) by week 8 of treatment
Prazo: 8 weeks

for each experimental treatment arm compared to the SOC treatment arm.

8 weeks

Medidas de resultados secundários

Medida de resultado
Prazo
Proporção cumulativa de participantes com conversão estável de cultura de escarro na semana 8, conforme medido pelo status de cultura negativa por meio de cultura líquida MGIT em duas medições consecutivas.
Prazo: 8 semanas
8 semanas
Inclinação média do log10 TTP das medições longitudinais da cultura líquida MGIT durante as primeiras 8 semanas de tratamento.
Prazo: Semanas 0, 1, 2, 3, 4, 6 e 8
Semanas 0, 1, 2, 3, 4, 6 e 8
Proporção cumulativa de participantes com um novo EA de Grau 3 ou superior na semana 26 de tratamento.
Prazo: 26 semanas
26 semanas
Proporção cumulativa de participantes com descontinuação permanente dos medicamentos anti-TB fornecidos pelo estudo devido a qualquer motivo antes da semana 8 de tratamento.
Prazo: 8 semanas
8 semanas
Proporção cumulativa de participantes com descontinuação permanente ou temporária por ≥3 dias de pelo menos um medicamento anti-TB por qualquer motivo antes da semana 8 de tratamento.
Prazo: 8 semanas
8 semanas
Proporção cumulativa de participantes com descontinuação permanente de pelo menos um medicamento anti-TB por qualquer motivo antes da 26ª semana de tratamento.
Prazo: 26 semanas
26 semanas
Um composto de conversão de cultura estável na semana 6 de tratamento e nenhum novo EA de Grau 3 ou superior até a semana 8.
Prazo: 8 semanas
8 semanas
Proporção de participantes com cura duradoura 52 semanas após o início do tratamento.
Prazo: 52 semanas
52 semanas

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Cadeira de estudo: Radojka Savic, PharmD, PhD, University of California
  • Cadeira de estudo: Kelly Dooley, MD, PhD, Vanderbilt University Medical Center
  • Cadeira de estudo: Gustavo Velásquez, MD, MPH, University of California

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de março de 2025

Conclusão Primária (Estimado)

1 de março de 2027

Conclusão do estudo (Estimado)

3 de janeiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

20 de dezembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de dezembro de 2023

Primeira postagem (Real)

5 de janeiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual participant data that underlie results in the publication, after deidentification.

Prazo de Compartilhamento de IPD

Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.

Critérios de acesso de compartilhamento IPD

  • With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
  • For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
  • By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever